Welcome to the CRL Insurer Services blog! Here you will find commentary from our dedicated team of medical directors and industry leaders on lab research and trends, innovative services and solutions, and what’s new at CRL. Click the button below to get the latest news directly to your inbox. Questions? Contact us at ILSsales@crlcorp.com.
Dr. Michael Fulks comments on the results of a recent study of Donanemab, an antibody that targets the amyloid-β (Aβ)… Read More
Tags: Alzheimers, Cardiovascular, Dementia, Risk
If you would like to sign up to receive email updates from the Insurer team, please click here.